A Phase 2a, Double-Blinded, Multi-Center, Escalating Dose Group, Placebo Controlled, Cross-Over Study to Evaluate the Safety, Efficacy and Tolerability of Subcutaneously Administered PL-3994 for the Treatment of Patients With Mild to Moderate Asthma.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 18 Dec 2014
At a glance
- Drugs PL 3994 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Palatin Technologies
- 15 Dec 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 28 Feb 2014 Planned initiation date changed from 1 Jan 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 26 Aug 2013 Planned initiation date changed from 1 May 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.